Dr Yohann Loriot, a medical oncologist at Institut Gustave Roussy in Villejuif, presented practice-changing data from the THOR trial. This study investigated the efficacy of the FGFR inhibitor erdafitinib in patients with advanced urothelial cancer with FGFR2/3 aberrations who had failed 1 or 2 prior lines of treatment. The presentation highlighted the importance of testing all patients with metastatic urothelial cancer for FGFR mutations based on the favorable outcomes observed.
With the educational support of:
